1. Home
  2. LOPE vs NAMS Comparison

LOPE vs NAMS Comparison

Compare LOPE & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LOPE

Grand Canyon Education Inc.

HOLD

Current Price

$140.90

Market Cap

4.5B

Sector

Real Estate

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$30.13

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOPE
NAMS
Founded
1949
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
4.1B
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
LOPE
NAMS
Price
$140.90
$30.13
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$220.00
$46.75
AVG Volume (30 Days)
256.4K
1.0M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.80
N/A
Revenue
$511,257,000.00
N/A
Revenue This Year
$8.67
$17.96
Revenue Next Year
$6.66
$540.65
P/E Ratio
$50.61
N/A
Revenue Growth
N/A
N/A
52 Week Low
$140.94
$17.76
52 Week High
$223.04
$42.21

Technical Indicators

Market Signals
Indicator
LOPE
NAMS
Relative Strength Index (RSI) 30.53 38.50
Support Level N/A $28.19
Resistance Level $174.73 $37.27
Average True Range (ATR) 4.47 1.65
MACD -0.47 -0.25
Stochastic Oscillator 11.03 16.99

Price Performance

Historical Comparison
LOPE
NAMS

About LOPE Grand Canyon Education Inc.

Grand Canyon Education Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases, and certificates across nine colleges, both online and on the ground at its campus in Phoenix, Arizona, and at four off-site classroom andlaboratory sites. The Company generates all of its revenue through service agreements with its university partners.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: